Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Abstract A004: Radiotherapy sensitizes preclinical models to DNA damage response agents

Pablo Binder, Theoni Katopodi, Lyndsey Hanson, Charlotte R. Bell, Eimear Flanagan, Paul Farrington, Nick Moore, Emily Wright, Yin Xin Ho, Tobias Bunday, Stewart Brown, Amy Cantrell, Yael Mamane, Jon Greenall, Shannon Sharman, John Woolley, Lorraine M. Mooney, Jane Kendrew

Mol Cancer Ther (2024) 23 (6_Supplement): A004.

https://doi.org/10.1158/1538-8514.SYNTHLETH24-A004

Published: 10 June 2024

View articletitled, Abstract A004: Radiotherapy sensitizes preclinical models to DNA damage response agents

Journal Articles

Abstract A151: Establishing assays to investigate combinations of fractioned radiotherapy with DNA damage response agents in vitro and in vivo to enable investigation of radiosensitization and improved anti-tumour responses

Charlotte Bell, Stewart Brown, Amy Cantrell, Paul Farrington, Miguel Garcia, Ben Hodgson, Yin Xin Ho, Allan Jordan, Theoni Katopodi, Jane Kendrew, Wen Hao Neo, Stuart Thomson, Graeme E Walker, Emily Wright

Mol Cancer Ther (2023) 22 (12_Supplement): A151.

https://doi.org/10.1158/1535-7163.TARG-23-A151

Published: 01 December 2023

View articletitled, Abstract A151: Establishing assays to investigate combinations of fractioned radiotherapy with DNA damage response agents in vitro and in vivo to enable investigation of radiosensitization and improved anti-tumour responses

Journal Articles

Abstract P051: Identification of an orally bioavailable dual Cyclin K glue degrader - CDK12/13 inhibitor

Edward K. Ainscow, Adrian Campbell, Michael Cripps, Robert Workman, Stuart Thomson, Kam Chohan, Damien Crepin, Mahiro Sunose, Jamie Patient, Jane Kendrew, Ash Bahl

Mol Cancer Ther (2021) 20 (12_Supplement): P051.

https://doi.org/10.1158/1535-7163.TARG-21-P051

Published: 01 December 2021

View articletitled, Abstract P051: Identification of an orally bioavailable dual Cyclin K glue degrader - CDK12/13 inhibitor

Journal Articles

Abstract A152: Novel autotaxin inhibitory antibodies block lysophosphatidic acid production in plasma and tumour cell proliferation in vitro

Sarah Ross, Scott Collins, Jelena Jovanovic, Jane Kendrew, Simon Barry, Swami Rathanaswami, Blakey David, Hazel Weir

Mol Cancer Ther (2015) 14 (12_Supplement_2): A152.

https://doi.org/10.1158/1535-7163.TARG-15-A152

Published: 01 December 2015

View articletitled, Abstract A152: Novel autotaxin inhibitory antibodies block lysophosphatidic acid production in plasma and tumour cell proliferation in vitro

Journal Articles

Abstract C135: AZ’4425 is a potent, selective, and orally bio-available progesterone receptor antagonist that has shown anti-tumor activity and inhibition of cancer stem cell proliferation.

Christine M. Chresta, Denis Alferez, Georgia Cerillo, Emma Still, Adina Hughes, Graeme Walker, Jane Kendrew, Claire Sadler, Jayne Harris, Iain Simpson, Andrew P. Thomas, Al Rabow, Robert Clarke, Sacha Howell, Graham Richmond

Mol Cancer Ther (2013) 12 (11_Supplement): C135.

https://doi.org/10.1158/1535-7163.TARG-13-C135

Published: 01 November 2013

View articletitled, Abstract C135: AZ’4425 is a potent, selective, and orally bio-available progesterone receptor antagonist that has shown anti-tumor activity and inhibition of cancer stem cell proliferation.

Journal Articles

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

David W. Jenkins, Sarah Ross, Margaret Veldman-Jones, Ian N. Foltz, Brandon C. Clavette, Kathy Manchulenko, Cath Eberlein, Jane Kendrew, Philip Petteruti, Song Cho, Melissa Damschroder, Li Peng, Dawn Baker, Neil R. Smith, Hazel M. Weir, David C. Blakey, Vahe Bedian, Simon T. Barry

Mol Cancer Ther (2012) 11 (8): 1650–1660.

https://doi.org/10.1158/1535-7163.MCT-11-1027

Published: 08 August 2012

View articletitled, MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

Includes: Supplementary data

Journal Articles

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

Mol Cancer Ther (2011) 10 (5): 861–873.

https://doi.org/10.1158/1535-7163.MCT-10-0976

Published: 08 May 2011

View articletitled, Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

Includes: Supplementary data

Journal Articles

An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding

Jane Kendrew, Cath Eberlein, Brad Hedberg, Karen McDaid, Neil R. Smith, Hazel M. Weir, Stephen R. Wedge, David C. Blakey, Ian Foltz, Joe Zhou, Jaspal S. Kang, Simon T. Barry

Mol Cancer Ther (2011) 10 (5): 770–783.

https://doi.org/10.1158/1535-7163.MCT-10-0876

Published: 08 May 2011

View articletitled, An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding

Journal Articles

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Jeffrey L. Brown, Z. Alexander Cao, Maria Pinzon-Ortiz, Jane Kendrew, Corinne Reimer, Shenghua Wen, Joe Q. Zhou, Mohammad Tabrizi, Steve Emery, Brenda McDermott, Lourdes Pablo, Patricia McCoon, Vahe Bedian, David C. Blakey

Mol Cancer Ther (2010) 9 (1): 145–156.

https://doi.org/10.1158/1535-7163.MCT-09-0554

Published: 12 January 2010

View articletitled, A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Includes: Supplementary data

Journal Articles

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts

Neil R. Smith, Neil H. James, Ian Oakley, Anna Wainwright, Clive Copley, Jane Kendrew, Lynsey M. Womersley, Juliane M. Jürgensmeier, Stephen R. Wedge, Simon T. Barry

Mol Cancer Ther (2007) 6 (8): 2198–2208.

https://doi.org/10.1158/1535-7163.MCT-07-0142

Published: 15 August 2007

View articletitled, Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts

Journal Articles

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

David McKillop, Elizabeth A. Partridge, John V. Kemp, Mike P. Spence, Jane Kendrew, Sharon Barnett, Phillippa G. Wood, Petrina B. Giles, Andrew B. Patterson, Francis Bichat, Nicolas Guilbaud, Trevor C. Stephens

Mol Cancer Ther (2005) 4 (4): 641–649.

https://doi.org/10.1158/1535-7163.MCT-04-0329

Published: 12 April 2005

View articletitled, Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract A004: Radiotherapy sensitizes preclinical models to DNA damage response agents

Abstract A151: Establishing assays to investigate combinations of fractioned radiotherapy with DNA damage response agents in vitro and in vivo to enable investigation of radiosensitization and improved anti-tumour responses

Abstract P051: Identification of an orally bioavailable dual Cyclin K glue degrader - CDK12/13 inhibitor

Abstract A152: Novel autotaxin inhibitory antibodies block lysophosphatidic acid production in plasma and tumour cell proliferation in vitro

Abstract C135: AZ’4425 is a potent, selective, and orally bio-available progesterone receptor antagonist that has shown anti-tumor activity and inhibition of cancer stem cell proliferation.

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only